HCV相关肝硬化抗病毒治疗现状

李强; 黄玉仙; 陈良

doi:10.3969/j.issn.1001-5256.2015.11.011

HCV相关肝硬化抗病毒治疗现状

DOI: 10.3969/j.issn.1001-5256.2015.11.011

复旦大学附属公共卫生临床中心肝炎一科

基金项目:

上海市科委“科技创新行动计划”医学与农业领域重点项目(13401902100)；上海市卫生局临床医学应用研究项目(20114279)；

详细信息

中图分类号: R512.63
计量
- 文章访问数: 2227
- HTML全文浏览量: 13
- PDF下载量: 544
- 被引次数: 0
出版历程
- 出版日期: 2015-11-20

Present situation of antiviral therapies for HCV-related cirrhosis

Research funding:

摘要

摘要:
HCV相关肝硬化患者发生肝功能衰竭和肝细胞癌的风险高于非肝硬化患者。抗病毒治疗能够降低HCV相关肝硬化患者肝功能衰竭和肝细胞癌的发生率。介绍了目前HCV相关肝硬化患者抗病毒方案:聚乙二醇干扰素（PEG-IFN）α联合利巴韦林（RBV）（P/R）、直接抗病毒药物（DAA）+P/R和无干扰素（IFN）方案,总结了HCV相关肝硬化患者的抗病毒治疗现状。认为DAA的出现提高了HCV相关肝硬化的持续病毒学应答率、降低了不良反应发生率,无IFN方案在HCV相关肝硬化患者抗病毒治疗中具有很大的优势和应用前景。
- 肝炎病毒属 /
- 肝硬化 /
- 抗病毒药 /
- 治疗
Abstract:
Patients with hepatitis C virus( HCV)-related cirrhosis are at a higher risk for the development of hepatic failure and hepatocellular carcinoma( HCC) compared with non-cirrhotic patients. Antiviral therapies for HCV-related cirrhosis may reduce the incidence of HCC and hepatic failure. This article introduces current antiviral therapies for HCV-related cirrhosis: P / R,DAA + P / R,and IFN-free regimens,and summarizes the present situation of antiviral therapies for HCV-related cirrhosis. It is thought that the advent of direct-acting antivirals has improved the rate of sustained virologic response and reduced the incidence of adverse events during the treatment of HCV-related cirrhosis. Interferon-free regimens have great advantage and potential in antiviral therapies for HCV-related cirrhosis.
- hepacivirus /
- liver cirrhosis /
- antiviral agents /
- therapy